Global Aneurysmal Subarachnoid Hemorrhage Drugs

Aneurysmal Subarachnoid Hemorrhage Drugs Comprehensive Study by Type (Opioid Analgesic, Calcium Channel Blocker, Anticonvulsant, Stool Softener, Osmotic Agent, Other Drugs), End User (Hospitals, Clinics, Homecare) Players and Region - Global Market Outlook to 2030

Aneurysmal Subarachnoid Hemorrhage Drugs Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Aneurysmal Subarachnoid Hemorrhage Drugs Market Overview:
Aneurysmal subarachnoid hemorrhage (ASH) is a type of stroke that is life-threatening. The aneurysmal subarachnoid hemorrhage drugs market is driven by an increase in the elderly population and a rise in the incidence of brain clots. In addition, the high incidence of hypertension and chronic diseases, increase in health care spending, and favorable reimbursement scenario is expected to boost the global aneurysmal subarachnoid hemorrhage drugs market in the forecasted period. Furthermore, the existing market players are involved in the development of new drugs which in turn propel the market growth.

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Increasing Investment in Research and Development

Market Growth Drivers:
Surge in Geriatric Population and High Prevalence of Population Suffering from Hypertension and Changing Lifestyle with Increase the Risk of aSAH

Challenges:
Stringent Government Rules and Regulations for Drug Approval

Restraints:
Side Effects of Drugs and Medication Taken during the Treatment of Aneurysmal Subarachnoid Hemorrhage

Opportunities:
Growth in the Healthcare Industry Worldwide, Huge Investment by Major Players and Growing Demand for Advanced and Effective Drugs

Competitive Landscape:
The companies are now exploring the market by adopting mergers & acquisitions, expansions, investments, new developments in existing products, and collaborations as their preferred strategies. The players are also exploring new geographies and industries through expansions and acquisitions so as to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Arbor Pharmaceuticals (United States), Edge Therapeutics (United States), Johnson & Johnson (United States), Mylan N.V (United States), Orexo AB (Sweden), Pfizer (United States), Purdue Pharma (United States), Pharmaxis (Australia), Sun Pharmaceutical Industries (India) and Teva Pharmaceutical (Israel). Analyst at AMA Research see United States Players to retain maximum share of Global Aneurysmal Subarachnoid Hemorrhage Drugs market by 2030. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Aneurysmal Subarachnoid Hemorrhage Drugs market.

What Can be Explored with the Aneurysmal Subarachnoid Hemorrhage Drugs Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Aneurysmal Subarachnoid Hemorrhage Drugs Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Aneurysmal Subarachnoid Hemorrhage Drugs
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Aneurysmal Subarachnoid Hemorrhage Drugs market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Aneurysmal Subarachnoid Hemorrhage Drugs market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers of Aneurysmal Subarachnoid Hemorrhage Drugs, Suppliers and Distributors of Aneurysmal Subarachnoid Hemorrhage Drugs, End-Users, Potential Investors, Market Research Firms, Regulatory Bodies and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Opioid Analgesic
  • Calcium Channel Blocker
  • Anticonvulsant
  • Stool Softener
  • Osmotic Agent
  • Other Drugs
By End User
  • Hospitals
  • Clinics
  • Homecare

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Surge in Geriatric Population and High Prevalence of Population Suffering from Hypertension
      • 3.2.2. Changing Lifestyle with Increase the Risk of aSAH
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations for Drug Approval
    • 3.4. Market Trends
      • 3.4.1. Increasing Investment in Research and Development
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs, by Type, End User and Region (value and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs (Value)
      • 5.2.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: Type (Value)
        • 5.2.1.1. Opioid Analgesic
        • 5.2.1.2. Calcium Channel Blocker
        • 5.2.1.3. Anticonvulsant
        • 5.2.1.4. Stool Softener
        • 5.2.1.5. Osmotic Agent
        • 5.2.1.6. Other Drugs
      • 5.2.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: End User (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Homecare
      • 5.2.3. Global Aneurysmal Subarachnoid Hemorrhage Drugs Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Aneurysmal Subarachnoid Hemorrhage Drugs (Price)
      • 5.3.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: Type (Price)
  • 6. Aneurysmal Subarachnoid Hemorrhage Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Arbor Pharmaceuticals (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Edge Therapeutics (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Mylan N.V (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Orexo AB (Sweden)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pfizer (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Purdue Pharma (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Pharmaxis (Australia)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sun Pharmaceutical Industries (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Teva Pharmaceutical (Israel)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Aneurysmal Subarachnoid Hemorrhage Drugs Sale, by Type, End User and Region (value and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs (Value)
      • 7.2.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: Type (Value)
        • 7.2.1.1. Opioid Analgesic
        • 7.2.1.2. Calcium Channel Blocker
        • 7.2.1.3. Anticonvulsant
        • 7.2.1.4. Stool Softener
        • 7.2.1.5. Osmotic Agent
        • 7.2.1.6. Other Drugs
      • 7.2.2. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: End User (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Homecare
      • 7.2.3. Global Aneurysmal Subarachnoid Hemorrhage Drugs Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Aneurysmal Subarachnoid Hemorrhage Drugs (Price)
      • 7.3.1. Global Aneurysmal Subarachnoid Hemorrhage Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aneurysmal Subarachnoid Hemorrhage Drugs: by Type(USD Million)
  • Table 2. Aneurysmal Subarachnoid Hemorrhage Drugs Opioid Analgesic , by Region USD Million (2018-2023)
  • Table 3. Aneurysmal Subarachnoid Hemorrhage Drugs Calcium Channel Blocker , by Region USD Million (2018-2023)
  • Table 4. Aneurysmal Subarachnoid Hemorrhage Drugs Anticonvulsant , by Region USD Million (2018-2023)
  • Table 5. Aneurysmal Subarachnoid Hemorrhage Drugs Stool Softener , by Region USD Million (2018-2023)
  • Table 6. Aneurysmal Subarachnoid Hemorrhage Drugs Osmotic Agent , by Region USD Million (2018-2023)
  • Table 7. Aneurysmal Subarachnoid Hemorrhage Drugs Other Drugs , by Region USD Million (2018-2023)
  • Table 8. Aneurysmal Subarachnoid Hemorrhage Drugs: by End User(USD Million)
  • Table 9. Aneurysmal Subarachnoid Hemorrhage Drugs Hospitals , by Region USD Million (2018-2023)
  • Table 10. Aneurysmal Subarachnoid Hemorrhage Drugs Clinics , by Region USD Million (2018-2023)
  • Table 11. Aneurysmal Subarachnoid Hemorrhage Drugs Homecare , by Region USD Million (2018-2023)
  • Table 12. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2018-2023)
  • Table 13. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 14. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 15. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 16. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 17. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 18. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 19. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 20. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 21. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2018-2023)
  • Table 22. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 23. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 24. China Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 25. China Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 26. Japan Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 27. Japan Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 28. India Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 29. India Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 30. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 31. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 32. Taiwan Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 33. Taiwan Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 34. Australia Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 35. Australia Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 36. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 37. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 38. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2018-2023)
  • Table 39. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 40. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 41. Germany Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 42. Germany Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 43. France Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 44. France Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 45. Italy Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 46. Italy Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 47. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 48. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 49. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 50. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 51. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 52. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 53. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2018-2023)
  • Table 54. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 55. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 56. Middle East Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 57. Middle East Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 58. Africa Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 59. Africa Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 60. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2018-2023)
  • Table 61. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 62. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 63. United States Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 64. United States Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 65. Canada Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 66. Canada Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 67. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2018-2023)
  • Table 68. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2018-2023)
  • Table 69. Aneurysmal Subarachnoid Hemorrhage Drugs: by Type(USD/Units)
  • Table 70. Company Basic Information, Sales Area and Its Competitors
  • Table 71. Company Basic Information, Sales Area and Its Competitors
  • Table 72. Company Basic Information, Sales Area and Its Competitors
  • Table 73. Company Basic Information, Sales Area and Its Competitors
  • Table 74. Company Basic Information, Sales Area and Its Competitors
  • Table 75. Company Basic Information, Sales Area and Its Competitors
  • Table 76. Company Basic Information, Sales Area and Its Competitors
  • Table 77. Company Basic Information, Sales Area and Its Competitors
  • Table 78. Company Basic Information, Sales Area and Its Competitors
  • Table 79. Company Basic Information, Sales Area and Its Competitors
  • Table 80. Aneurysmal Subarachnoid Hemorrhage Drugs: by Type(USD Million)
  • Table 81. Aneurysmal Subarachnoid Hemorrhage Drugs Opioid Analgesic , by Region USD Million (2025-2030)
  • Table 82. Aneurysmal Subarachnoid Hemorrhage Drugs Calcium Channel Blocker , by Region USD Million (2025-2030)
  • Table 83. Aneurysmal Subarachnoid Hemorrhage Drugs Anticonvulsant , by Region USD Million (2025-2030)
  • Table 84. Aneurysmal Subarachnoid Hemorrhage Drugs Stool Softener , by Region USD Million (2025-2030)
  • Table 85. Aneurysmal Subarachnoid Hemorrhage Drugs Osmotic Agent , by Region USD Million (2025-2030)
  • Table 86. Aneurysmal Subarachnoid Hemorrhage Drugs Other Drugs , by Region USD Million (2025-2030)
  • Table 87. Aneurysmal Subarachnoid Hemorrhage Drugs: by End User(USD Million)
  • Table 88. Aneurysmal Subarachnoid Hemorrhage Drugs Hospitals , by Region USD Million (2025-2030)
  • Table 89. Aneurysmal Subarachnoid Hemorrhage Drugs Clinics , by Region USD Million (2025-2030)
  • Table 90. Aneurysmal Subarachnoid Hemorrhage Drugs Homecare , by Region USD Million (2025-2030)
  • Table 91. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2025-2030)
  • Table 92. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 93. South America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 94. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 95. Brazil Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 96. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 97. Argentina Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 98. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 99. Rest of South America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 100. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2025-2030)
  • Table 101. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 102. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 103. China Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 104. China Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 105. Japan Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 106. Japan Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 107. India Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 108. India Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 109. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 110. South Korea Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 111. Taiwan Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 112. Taiwan Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 113. Australia Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 114. Australia Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 115. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 116. Rest of Asia-Pacific Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 117. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2025-2030)
  • Table 118. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 119. Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 120. Germany Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 121. Germany Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 122. France Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 123. France Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 124. Italy Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 125. Italy Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 126. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 127. United Kingdom Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 128. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 129. Netherlands Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 130. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 131. Rest of Europe Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 132. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2025-2030)
  • Table 133. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 134. MEA Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 135. Middle East Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 136. Middle East Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 137. Africa Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 138. Africa Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 139. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by Country USD Million (2025-2030)
  • Table 140. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 141. North America Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 142. United States Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 143. United States Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 144. Canada Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 145. Canada Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 146. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs, by Type USD Million (2025-2030)
  • Table 147. Mexico Aneurysmal Subarachnoid Hemorrhage Drugs, by End User USD Million (2025-2030)
  • Table 148. Aneurysmal Subarachnoid Hemorrhage Drugs: by Type(USD/Units)
  • Table 149. Research Programs/Design for This Report
  • Table 150. Key Data Information from Secondary Sources
  • Table 151. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by Type USD Million (2018-2023)
  • Figure 5. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by End User USD Million (2018-2023)
  • Figure 6. South America Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 7. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 8. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 9. MEA Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 10. North America Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 11. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by Type USD/Units (2018-2023)
  • Figure 12. Global Aneurysmal Subarachnoid Hemorrhage Drugs share by Players 2023 (%)
  • Figure 13. Global Aneurysmal Subarachnoid Hemorrhage Drugs share by Players (Top 3) 2023(%)
  • Figure 14. Global Aneurysmal Subarachnoid Hemorrhage Drugs share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Arbor Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Arbor Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 18. Edge Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 19. Edge Therapeutics (United States) Revenue: by Geography 2023
  • Figure 20. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 21. Johnson & Johnson (United States) Revenue: by Geography 2023
  • Figure 22. Mylan N.V (United States) Revenue, Net Income and Gross profit
  • Figure 23. Mylan N.V (United States) Revenue: by Geography 2023
  • Figure 24. Orexo AB (Sweden) Revenue, Net Income and Gross profit
  • Figure 25. Orexo AB (Sweden) Revenue: by Geography 2023
  • Figure 26. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 27. Pfizer (United States) Revenue: by Geography 2023
  • Figure 28. Purdue Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 29. Purdue Pharma (United States) Revenue: by Geography 2023
  • Figure 30. Pharmaxis (Australia) Revenue, Net Income and Gross profit
  • Figure 31. Pharmaxis (Australia) Revenue: by Geography 2023
  • Figure 32. Sun Pharmaceutical Industries (India) Revenue, Net Income and Gross profit
  • Figure 33. Sun Pharmaceutical Industries (India) Revenue: by Geography 2023
  • Figure 34. Teva Pharmaceutical (Israel) Revenue, Net Income and Gross profit
  • Figure 35. Teva Pharmaceutical (Israel) Revenue: by Geography 2023
  • Figure 36. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by Type USD Million (2025-2030)
  • Figure 37. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by End User USD Million (2025-2030)
  • Figure 38. South America Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 39. Asia Pacific Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 40. Europe Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 41. MEA Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 42. North America Aneurysmal Subarachnoid Hemorrhage Drugs Share (%), by Country
  • Figure 43. Global Aneurysmal Subarachnoid Hemorrhage Drugs: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Arbor Pharmaceuticals (United States)
  • Edge Therapeutics (United States)
  • Johnson & Johnson (United States)
  • Mylan N.V (United States)
  • Orexo AB (Sweden)
  • Pfizer (United States)
  • Purdue Pharma (United States)
  • Pharmaxis (Australia)
  • Sun Pharmaceutical Industries (India)
  • Teva Pharmaceutical (Israel)
Select User Access Type

Key Highlights of Report


Jan 2024 206 Pages 75 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Aneurysmal Subarachnoid Hemorrhage Drugs Quantitative research analysis
Global Aneurysmal Subarachnoid Hemorrhage Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Aneurysmal Subarachnoid Hemorrhage Drugs market are Arbor Pharmaceuticals (United States), Edge Therapeutics (United States), Johnson & Johnson (United States), Mylan N.V (United States), Orexo AB (Sweden), Pfizer (United States), Purdue Pharma (United States), Pharmaxis (Australia), Sun Pharmaceutical Industries (India) and Teva Pharmaceutical (Israel), to name a few.
"Increasing Investment in Research and Development" is seen as one of major influencing trends for Aneurysmal Subarachnoid Hemorrhage Drugs Market during projected period 2023-2030.
Opioid Analgesic segment in Global market to hold robust market share owing to "Surge in Geriatric Population and High Prevalence of Population Suffering from Hypertension ".

Know More About Global Aneurysmal Subarachnoid Hemorrhage Drugs Report?

Have a Query? Click Here

Other Related Reports

Opioids Agonist Drugs Comprehensive Study by Type (Morphine, Codeine, Fentanyl, Meperidine), Application (Pain Management, Cough Supression, Diarrhea Suppresion), Receptor Binding (Strong Agonist, Mi...
$ 3350
Citicoline Comprehensive Study by Form (Tablet, Capsule, Powder), Indication (Alzheimer’s Disease, Dementia, Head Trauma, Cerebral Ischemic Stroke, Cognitive Impairment, Others), Distribution (Hospit...
$ 3650
Recombinant Vaccines Comprehensive Study by Type (Subunit Recombinant Vaccines, Attenuated Recombinant Vaccines, Vector Recombinant Vaccines), Application (Recombinant Human Vaccines, Animal Recombin...
$ 3650
Serotonin Suppliment Comprehensive Study by Type (Tablets, Capsules, Liquid and Sprays, Others), Application (Depression Treatment, Anxiety Treatment, Others), Sales Channel (Over the Counter (OTC), ...
$ 3450
Revlimid Drug Comprehensive Study by Application (Hospital, Drugs Store, Other), Dosage (10mg, 25mg, Other) Players and Region - Global Market Outlook to 2026
$ 3500
Prescription Drugs Comprehensive Study by Type (Opinoids, Stimulants, Depressants), Application (Hospital, Clinic, Other), End users (Adults, Children), Drug type (Brand Drugs, Generic Drug), Distrib...
$ 3350